Balyasny Asset Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Balyasny Asset Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$49.8M	Buy	539,031 +253,161	+89%	+$23.8M	0.06%	350
2025 Q4	$22.6M	Sell	285,870 -31,280	-10%	-$2.25M	0.03%	653
2025 Q3	$23.3M	Buy	+317,150	New	+$20.2M	0.03%	654
2025 Q2	–	Sell	-26,816	Closed	-$1.21M	–	3149
2025 Q1	$1.21M	Buy	26,816 +8,083	+43%	+$381K	﹤0.01%	1915
2024 Q4	$775K	Buy	+18,733	New	+$781K	﹤0.01%	2046
2024 Q2	–	Sell	-10,016	Closed	-$252K	–	2906
2024 Q1	$252K	Buy	+10,016	New	+$275K	﹤0.01%	2323
2023 Q4	–	Sell	-18,107	Closed	-$572K	–	2740
2023 Q3	$572K	Buy	+18,107	New	+$496K	﹤0.01%	1716
2023 Q2	–	Sell	-10,250	Closed	-$246K	–	2595
2023 Q1	$246K	Buy	+10,250	New	+$234K	﹤0.01%	2176

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Balyasny Asset Management's MIRM Position: Q1 2026 in Review

Balyasny Asset Management increased its Mirum Pharmaceuticals (MIRM) stake by 89% in Q1 2026, buying an estimated $23.8M and bringing the position to 539,031 shares worth $49.8M. The position accounts for 0.06% of the portfolio, ranked #350.

Balyasny Asset Management first reported a position in MIRM in Q1 2023 and has held it in 8 quarters since. 311 funds tracked by Wall St. Rank hold MIRM as of Q1 2026.

Balyasny Asset Management held 539,031 shares of Mirum Pharmaceuticals worth $49.8M as of Q1 2026.
Balyasny Asset Management bought 253,161 Mirum Pharmaceuticals shares in Q1 2026, an estimated $23.8M.
Mirum Pharmaceuticals made up 0.06% of Balyasny Asset Management's portfolio in Q1 2026, its #350 holding.
Balyasny Asset Management first reported a position in Mirum Pharmaceuticals in Q1 2023 and has held it in 8 quarters since.
311 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.